Dow Jones
32.244,58 +382,60 (+1,20%) Nasdaq
11.675,54 +45,02 (+0,39%) Nikkei 225
26.945,67 -388,12 (-1,42%) EUR/USD
1,0718 -0,0008 (-0,08%) Bitcoin EUR
26.057,75 +363,94 (+1,42%) CMC Crypto 200
604,70 +5,03 (+0,84%)
iCAD, Inc. (ICAD)
Dopo ore:
| Chiusura precedente | 1,2700 |
| Aperto | 1,2800 |
| Denaro | 0,0000 x 3200 |
| Lettera | 0,0000 x 1000 |
| Min-Max giorno | 1,1750 - 1,2981 |
| Intervallo di 52 settimane | 1,1600 - 4,6800 |
| Volume | |
| Media Volume | 148.418 |
| Capitalizzazione | 31,935M |
| Beta (5 anni mensile) | 1,21 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5700 |
| Prossima data utili | 28 mar 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,00 |
- GlobeNewswire
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
Company is exploring strategic options for its Therapy business lineNASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023. Based on preliminary, unaudited financial information,
- GlobeNewswire
iCAD Announces Leadership Transition
Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO, remains Chairman of the Board NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has accepted the resignation, for personal reasons, of Stacey Stevens as President and CEO. Stacey will remain with the Company through April 30, 2023
- GlobeNewswire
New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists’ Efficiency and Accuracy
Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023NASHUA, N.H., March 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world clinical evidence to be presented at the European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI® boosts radiologists’ efficiency and accuracy. The
